Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers in Israel and the United States. The company is developing AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. The company was incorporated in 1987 and is based in Monmouth Junction, New Jersey.
Metrics to compare | ADXS | Peers Peers - average of corresponding metrics from companies closely matching ADXS: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipADXSPeersSector |
|---|---|---|---|---|
P/E Ratio | 0.0x | 0.0x | 0.0x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 0.0x | 0.0x | |
Price / LTM Sales | 0.0x | 0.0x | 0.0x | |
Upside (Analyst Target) | 0.0% | 0.0% | 0.0% | |
Fair Value Upside | Unlock | 0.0% | 0.0% | Unlock |